You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 7, 2025

CLINICAL TRIALS PROFILE FOR DEFEROXAMINE MESYLATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Deferoxamine Mesylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00598572 ↗ Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage Completed Hartford Hospital Phase 1 2008-07-01 Animal studies show that the breakdown of blood results in iron accumulation in the brain after brain hemorrhage (ICH); and that iron plays a role in brain injury in ICH patients. Deferoxamine (DFO) has been extensively used in clinical practice for more than 30 years to remove excessive iron from the body, and has been shown to provide some benefit in animal studies of ICH. Therefore, we plan to undertake this study to evaluate the safety and tolerability of treatment with DFO in patients with ICH, and to determine the maximal tolerated dose to be used in future studies to determine if treatment with DFO can improve the outcome of patients with ICH. Our main objectives are: 1) to evaluate the safety and tolerability of varying doses of DFO, by determining the treatment related adverse events, in patients with ICH; and 2) to determine the maximal tolerated dose to be adopted in subsequent studies to test the efficacy of DFO in improving outcome after ICH. We hypothesize that DFO is well-tolerated and has minimal serious adverse effects in patients with ICH; and that treatment with DFO will improve patients' outcome. The results can potentially bring into account new means to improve the outcome of patients with ICH. ICH is a frequent cause of disability and death. A successful study demonstrating the efficacy of iron-modifying therapy would be of considerable public health significance.
NCT00598572 ↗ Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage Completed Massachusetts General Hospital Phase 1 2008-07-01 Animal studies show that the breakdown of blood results in iron accumulation in the brain after brain hemorrhage (ICH); and that iron plays a role in brain injury in ICH patients. Deferoxamine (DFO) has been extensively used in clinical practice for more than 30 years to remove excessive iron from the body, and has been shown to provide some benefit in animal studies of ICH. Therefore, we plan to undertake this study to evaluate the safety and tolerability of treatment with DFO in patients with ICH, and to determine the maximal tolerated dose to be used in future studies to determine if treatment with DFO can improve the outcome of patients with ICH. Our main objectives are: 1) to evaluate the safety and tolerability of varying doses of DFO, by determining the treatment related adverse events, in patients with ICH; and 2) to determine the maximal tolerated dose to be adopted in subsequent studies to test the efficacy of DFO in improving outcome after ICH. We hypothesize that DFO is well-tolerated and has minimal serious adverse effects in patients with ICH; and that treatment with DFO will improve patients' outcome. The results can potentially bring into account new means to improve the outcome of patients with ICH. ICH is a frequent cause of disability and death. A successful study demonstrating the efficacy of iron-modifying therapy would be of considerable public health significance.
NCT00598572 ↗ Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage Completed Medical College of Wisconsin Phase 1 2008-07-01 Animal studies show that the breakdown of blood results in iron accumulation in the brain after brain hemorrhage (ICH); and that iron plays a role in brain injury in ICH patients. Deferoxamine (DFO) has been extensively used in clinical practice for more than 30 years to remove excessive iron from the body, and has been shown to provide some benefit in animal studies of ICH. Therefore, we plan to undertake this study to evaluate the safety and tolerability of treatment with DFO in patients with ICH, and to determine the maximal tolerated dose to be used in future studies to determine if treatment with DFO can improve the outcome of patients with ICH. Our main objectives are: 1) to evaluate the safety and tolerability of varying doses of DFO, by determining the treatment related adverse events, in patients with ICH; and 2) to determine the maximal tolerated dose to be adopted in subsequent studies to test the efficacy of DFO in improving outcome after ICH. We hypothesize that DFO is well-tolerated and has minimal serious adverse effects in patients with ICH; and that treatment with DFO will improve patients' outcome. The results can potentially bring into account new means to improve the outcome of patients with ICH. ICH is a frequent cause of disability and death. A successful study demonstrating the efficacy of iron-modifying therapy would be of considerable public health significance.
NCT00598572 ↗ Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage Completed Medical University of South Carolina Phase 1 2008-07-01 Animal studies show that the breakdown of blood results in iron accumulation in the brain after brain hemorrhage (ICH); and that iron plays a role in brain injury in ICH patients. Deferoxamine (DFO) has been extensively used in clinical practice for more than 30 years to remove excessive iron from the body, and has been shown to provide some benefit in animal studies of ICH. Therefore, we plan to undertake this study to evaluate the safety and tolerability of treatment with DFO in patients with ICH, and to determine the maximal tolerated dose to be used in future studies to determine if treatment with DFO can improve the outcome of patients with ICH. Our main objectives are: 1) to evaluate the safety and tolerability of varying doses of DFO, by determining the treatment related adverse events, in patients with ICH; and 2) to determine the maximal tolerated dose to be adopted in subsequent studies to test the efficacy of DFO in improving outcome after ICH. We hypothesize that DFO is well-tolerated and has minimal serious adverse effects in patients with ICH; and that treatment with DFO will improve patients' outcome. The results can potentially bring into account new means to improve the outcome of patients with ICH. ICH is a frequent cause of disability and death. A successful study demonstrating the efficacy of iron-modifying therapy would be of considerable public health significance.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Deferoxamine Mesylate

Condition Name

Condition Name for Deferoxamine Mesylate
Intervention Trials
Intracerebral Hemorrhage 4
Acute Lymphoblastic Leukemia 1
Acute Myeloid Leukemia 1
Aneurysmal Subarachnoid Hemorrhage 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Deferoxamine Mesylate
Intervention Trials
Hemorrhage 5
Cerebral Hemorrhage 4
Preleukemia 1
Precursor Cell Lymphoblastic Leukemia-Lymphoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Deferoxamine Mesylate

Trials by Country

Trials by Country for Deferoxamine Mesylate
Location Trials
United States 37
Canada 7
China 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Deferoxamine Mesylate
Location Trials
Massachusetts 4
Michigan 3
Ohio 2
North Carolina 2
Maryland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Deferoxamine Mesylate

Clinical Trial Phase

Clinical Trial Phase for Deferoxamine Mesylate
Clinical Trial Phase Trials
Phase 2 3
Phase 1/Phase 2 1
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Deferoxamine Mesylate
Clinical Trial Phase Trials
Completed 2
Terminated 2
Unknown status 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Deferoxamine Mesylate

Sponsor Name

Sponsor Name for Deferoxamine Mesylate
Sponsor Trials
Hartford Hospital 3
Massachusetts General Hospital 3
Medical University of South Carolina 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Deferoxamine Mesylate
Sponsor Trials
Other 93
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Deferoxamine Mesylate: Clinical Trials, Market Analysis, and Projections

Introduction

Deferoxamine Mesylate, commonly known by its brand name Desferal, is a potent iron chelator used to treat iron overload conditions such as thalassemia, hemochromatosis, and transfusion-associated iron overload. This article provides an update on the current clinical trials, market analysis, and future projections for Deferoxamine Mesylate.

Clinical Trials Update

Ongoing and Recent Trials

Several clinical trials are ongoing or have recently concluded to evaluate the efficacy and safety of Deferoxamine Mesylate in various indications.

  • Cerebral Hemorrhage: A Phase 2 clinical trial (NCT02175225) has been conducted to assess the safety and efficacy of Deferoxamine Mesylate in patients with cerebral hemorrhage. This trial aimed to evaluate whether Deferoxamine Mesylate could reduce brain damage and improve outcomes in such patients[1][4].

  • Acute Ischemic Stroke: The TANDEM-1 trial, a multicenter, randomized, double-blind, placebo-controlled study, investigated the use of Deferoxamine Mesylate in patients with acute ischemic stroke. This study focused on the safety and tolerability of Deferoxamine Mesylate when administered alongside thrombolysis[4].

  • Iron Overload: Numerous studies have evaluated Deferoxamine Mesylate in the management of chronic iron overload due to blood transfusions. These studies have shown that Deferoxamine Mesylate effectively reduces serum ferritin levels, a key indicator of iron overload[3].

Safety and Efficacy

The safety profile of Deferoxamine Mesylate has been extensively studied. While it is generally well-tolerated, there are concerns about potential adverse effects such as allergic reactions and local irritation at the injection site. In the context of cerebral hemorrhage and acute ischemic stroke, the primary focus has been on ensuring that Deferoxamine Mesylate does not exacerbate bleeding risks[4].

Market Analysis

Market Size and Growth

The global Deferoxamine Mesylate market has been valued at USD 100 billion in 2023 and is projected to grow to USD 147.75 billion by 2031, with a Compound Annual Growth Rate (CAGR) of 5% from 2024 to 2031. This growth is driven by the increasing prevalence of iron overload diseases such as thalassemia and hemochromatosis, as well as improvements in healthcare infrastructure and treatment options[2][5].

Key Drivers

Several factors are driving the growth of the Deferoxamine Mesylate market:

  • Increasing Prevalence of Iron Overload Diseases: The rising incidence of conditions like thalassemia and hemochromatosis is a significant driver. Early diagnosis and treatment awareness among patients and healthcare professionals are also contributing to market growth[2].

  • Improvements in Healthcare Infrastructure: Enhancements in healthcare access, especially in developing nations, are making Deferoxamine Mesylate more accessible to a broader patient population[2].

  • Government Initiatives and Reimbursement Policies: Government efforts to improve healthcare access and favorable reimbursement regulations are supporting the market expansion[2].

  • Advancements in Treatment Technology: Improvements in medication delivery technology are enhancing treatment outcomes and patient compliance, further boosting the market[2].

Market Projections

Future Growth Trajectory

The Deferoxamine Mesylate market is expected to continue its strong growth trajectory due to several factors:

  • Expanding Therapeutic Uses: Ongoing research aims to extend the medicinal uses of Deferoxamine Mesylate, potentially opening up new market opportunities. For instance, its use in cerebral hemorrhage and acute ischemic stroke is being explored[4].

  • Increasing Demand: The demand for Deferoxamine Mesylate is anticipated to rise as more patients are diagnosed with iron overload conditions. This increased demand, coupled with advancements in treatment options, will drive market growth[2].

  • Regulatory Support: Continued regulatory support and the conduct of post-marketing studies to evaluate efficacy and safety in various patient populations will further solidify the market position of Deferoxamine Mesylate[3].

Key Players

Several pharmaceutical companies are key players in the Deferoxamine Mesylate market:

  • Novartis: Known for its brand name Desferal, Novartis has been a major player in the iron chelation therapy market[5].

  • Teva Pharmaceutical Industries: Teva is another significant player, contributing to the global supply of Deferoxamine Mesylate[5].

  • Intas Pharmaceuticals: Intas Pharmaceuticals is also a notable manufacturer and distributor of Deferoxamine Mesylate[5].

Conclusion

Deferoxamine Mesylate remains a crucial drug in the management of iron overload conditions. With ongoing clinical trials exploring its use in new indications and a strong market growth trajectory, it is clear that Deferoxamine Mesylate will continue to play a vital role in healthcare.

Key Takeaways

  • Deferoxamine Mesylate is a potent iron chelator used to treat iron overload conditions.
  • Ongoing clinical trials are evaluating its safety and efficacy in cerebral hemorrhage and acute ischemic stroke.
  • The global market for Deferoxamine Mesylate is projected to grow significantly, driven by increasing disease prevalence and improvements in healthcare infrastructure.
  • Key players include Novartis, Teva Pharmaceutical Industries, and Intas Pharmaceuticals.
  • Regulatory support and ongoing research are expected to further expand the market.

FAQs

What is Deferoxamine Mesylate used for?

Deferoxamine Mesylate is primarily used to treat iron overload conditions such as thalassemia, hemochromatosis, and transfusion-associated iron overload.

What are the current clinical trials focusing on for Deferoxamine Mesylate?

Current clinical trials are focusing on the use of Deferoxamine Mesylate in cerebral hemorrhage and acute ischemic stroke, in addition to its traditional use in managing iron overload.

What is the projected market size for Deferoxamine Mesylate by 2031?

The global Deferoxamine Mesylate market is expected to reach USD 147.75 billion by 2031, growing at a CAGR of 5% from 2024 to 2031.

Who are the key players in the Deferoxamine Mesylate market?

Key players include Novartis, Teva Pharmaceutical Industries, and Intas Pharmaceuticals.

What are the main drivers of the Deferoxamine Mesylate market growth?

The main drivers include the increasing prevalence of iron overload diseases, improvements in healthcare infrastructure, government initiatives, and advancements in treatment technology.

Sources

  1. Synapse: Deferoxamine Mesylate - Drug Targets, Indications, Patents.
  2. Market Research Intellect: Global Deferoxamine Mesylate Market Size and Projections.
  3. FDA: 021825Orig1s000MedR.pdf.
  4. MDPI: Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Cerebral Ischemia.
  5. OpenPR: Medical Deferoxamine Mesylate Market to Reflect Holistic Expansion with Significant CAGR by 2024-2032.

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.